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Abstract 
After 20 years of the first Nipah Virus (NiV) outbreak in the world, it re-emerged as the 
outbreak in India. WHO has recognized NiV as a potent epidemic threat to human health. 
Both animal-to-human and human-to-human transmission of zoonotic NiV has been 
documented. Fruit bat of Pteropodidae family is the natural reservoir of the virus. Thus, the 
territorial habitat of these bats is the high risk zone of NiV outbreak. The symptoms are very 
nonspecific and the pathogenicity of NiV is yet to be fully understood. Diagnosis of NiV 
infection still relies on molecular techniques. Till date, no drugs or vaccines against NiV has 
been approved. Some research have presented arrays of the possible treatment and 
prevention option, but without sure shot implications. So, appropriate precautions are the 
only currently available prevention option. Nepal is yet to experience a NiV outbreak but that 
does not undermine the risk posed to the general population. High risk countries including 
Nepal should be well prepared to tackle the possible outbreak in future. 
Keywords: Nipah virus, NiV, outbreak, Nepal 
*Corresponding Author 
Email: hiraj.diamond@gmail.com  
Introduction 
Outbreaks in glance 
In the past few years, the outbreak of Ebola virus 
was on high rise throughout the world. In 
counter response against the virus, vaccine was 
developed and was being tested in high risk 
zones of Democratic Republic of the Congo on 
19 May, 2018 [1]. Coincidentally on the same 
day, this was overshadowed by the news of the 
outbreak of the Nipah virus (NiV) in India. 
Initially three deaths were reported due to NiV 
infection. Since then 15 people have been tested 
positive for NiV, of which 13 are already dead. 
Other 16 suspected cases identified through 
contact tracing are under observation and at 
least 753 additional people are quarantined [2]. 
NiV is featured in the WHO list of blueprint 
priority diseases 2018 with potent epidemic 
threat demanding urgent research and 
development (R&D) action [3]. The first 
recorded outbreak of NiV occurred in 1998 in 
Malaysia following in Singapore in 1999. The 
outbreak involved severe respiratory illness in 
pigs and encephalitis in humans. Later outbreak 
involving human infections was reported from 
Bangladesh and India in 2001 [4,5]. Till date, 
more than 600 cases of NiV human infections 
has been documented. The outbreaks in Indian 
subcontinent have been recurrent [6]. Higher 
mortality of around 70% has been observed in 
Bangladesh and India, compared to mortality in 
Malaysia and Singapore outbreak [5]. This is 
probably due to higher engagement of the 
respiratory tract in the Bangladesh and India 
outbreaks, differences in pathogenicity of the 
viral strains and lack of advanced healthcare 
facilities [5]. 
Nipah Virus (NiV) 
NiV is a member of the family Paramyxoviridae, 
genus Henipavirus [4,7]. The name Nipah virus 
originated from Sungai Nipah, a Malaysian 
village reporting the onset of an outbreak in 
1998 [7]. NiV is a zoonotic virus. Both animal-to-
human transmission (from infected bats/pigs) 
and human-to-human transmission have been 
documented. During Malaysian and 
Singaporean outbreaks transmission occurred 
from infected pigs, an intermediate host. 
However during Bangladeshi and Indian 
outbreak, transmission occurred through 
consumption of fruits/sap contaminated with 
infectious bat secretions and also through 
Nepal Journal of Biotechnology. Dec.  2 018  Vol. 6, No. 1: 69-73 Shrestha and Bhattachan et al. 
 
 
 ©NJB, Biotechnology Society of Nepal                              70                                                Nepjol.info/index.php/njb 
 
human-to-human transmission. During this 
outbreak, no any intermediate host was reported 
owing to the lack of pig farms in the region [4,7].  
 
Figure 1. Adapted from “Nipah Virus Distribution 
Map,” by Centers for Disease Control and Prevention 
(CDC) 2018, available at: https://www.cdc.gov 
/vhf/nipah/outbreaks/distribution-map.html. 
Copyright 2018 by the CDC. Adapted with 
permission. 
Natural host 
The natural hosts of NiV are fruit bats belonging 
to the Pteropodidae family, Pteropus spp. in 
particular [4,8]. Geographical distribution of 
NiV and Pteropus overlaps, ranging from 
Madagascar to Australia; covering South Asia, 
South-East Asia and Oceania region (Figure 1). 
Besides, African fruit bats of Pteropodidae 
family were also tested positive for NiV 
antibodies indicating further geographical 
distribution of NiV to African territory. NiV has 
also been tested positive in other animals 
including pigs, horses, goats, sheep, cats and 
dogs but only during the outbreaks [4]. 
Distribution map of these bats published by 
WHO includes Nepal however exact 
distribution and population of these bats are still 
to be studied and reported from Nepal. 
Pathogenesis 
NiV contains a negative-strand RNA. The non-
segmented RNA contain six genes which 
encodes structural proteins of virus namely, 
fusion protein (F), glycoprotein (G), polymerase 
(L), matrix protein (M), nucleocapsid (N) and 
phosphoprotein (P). The P gene encodes 
additional three accessory proteins namely, C, V 
and W proteins [9,10]. 
V protein was the key determinants for 
pathogenesis in hamster and ferret infection 
model [11-13]. V proteins target multiple host 
proteins and thus suppress the host antiviral 
response. In addition, V proteins interact and 
suppress different signaling pathways. V protein 
suppress the dephosphorylation of melanoma 
differentiation-associated protein 5 (MDA5) thus 
inhibiting the activation of the interferon (IFN) β 
promoter [14-16]. V proteins also suppress the 
retinoic acid-inducible gene-I (RIG-I) dependent 
induction of IFN [17]. V proteins also block 
signaling through Toll-like receptors 7/9 (TLRs 
7/9) and suppress IFN induction [18,19]. V 
proteins interact with IFN-responsive signaling 
pathway preventing activation and nuclear 
accumulation [20,21]. Similarly, C proteins 
regulate early host proinflammatory response 
thereby contributing virulence [22]. C protein 
was responsible for respiratory diseases in a 
ferret infection model [11,12]. The exact 
molecular mechanism of the pathogenicity of 
NiV is still to be revealed. 
Signs and symptoms 
The incubation time of NiV ranges between 4-14 
days, and upto 45 days in some cases. Infections 
in human ranges from asymptomatic infection to 
acute respiratory infection, and fatal encephalitis 
in severe cases. Initial symptoms include 
headaches, influenza-like fever, myalgia (muscle 
pain), sore throat and vomiting. These 
symptoms are followed by acute encephalitis. 
Finally in severe cases, encephalitis and seizures 
occurs, leading to coma within 24-48 hrs. Fatality 
varies from 40% to 75%. Surviving cases are 
reported to demonstrate long-term sequel 
including persistent convulsions, personality 
change, seizure disorder, relapse and delayed 
onset encephalitis [4,7]. 
Diagnosis 
Initial signs and symptoms of NiV infection are 
nonspecific, thus accurate diagnosis is 
challenging especially during an outbreaks. IgM 
Elisa for NiV, Real-time polymerase chain 
reaction (RT-PCR) and viral isolation are the 
tests employed for diagnosis [4]. These tests 
demands higher technical expertise and 
resources challenging the effectiveness of 
immediate counter measures during an 
outbreak. 
Treatment 
Currently, no drugs or vaccines are approved 
for NiV infection. Supportive care with intensive 
care is the only recommended treatment [4,7]. 
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Favipiravir (T-705) has been demonstrated to 
inhibit NiV replication and transcription in 
Syrian hamster model, with twice daily oral 
administration for 14 days [23]. Ribavirin, which 
has broad spectrum anti-DNA and anti-RNA 
virus activity and can transverse the blood-brain 
barrier, was also reported to reduce mortality in 
an open-label trial [24]. 
Prevention 
Vaccines have not been developed against NiV. 
However, routine and thorough disinfection of 
pig farms can prevent the infection. Also, 
avoiding the consumption of the bat eaten fruits 
or saliva/urine contaminated fruits/sap can 
prevent the infection. Thus, public awareness of 
the associated risk factors is the only measure to 
reduce risk of NiV infection. During outbreaks, 
suspected animal premises should be 
quarantined and infected animals should be 
culled. Also, healthcare workers caring 
suspected or confirmed NiV infected patients 
should adhere to standard infection control 
precautions [4]. Personal protection, such as 
masks, goggles, gloves, gowns, and boots, is 
advocated for field and farm workers of NiV 
risk zones. Personal protection should be 
accompanied by hand-washing and disinfection 
of equipments for better prevention [5]. 
Future prospects 
Respiratory route administration of lipopeptides 
prevented NiV infection in both hamsters and 
non-human primates. Also, retention of peptides 
in respiratory tract avoided systemic delivery of 
NiV thus increasing safety and enhancing 
interventions [25]. Vaccines using a vesicular 
stomatitis virus vector have demonstrated 
protection against NiV in hamsters, ferrets and 
African green monkeys [26]. Recently in 
Australia, subunit vaccines using Hendra G 
protein have demonstrated protection against 
NiV in horses by producing cross-protective 
antibodies. This vaccine has potential for NiV 
protection in humans as well [7]. We could be on 
verge of testing vaccine against NiV soon. 
Nepalese prospects 
Till date no outbreak of NiV or NiV confirmed 
mortality has been documented within the 
territory of Nepal. No research has been done on 
surveilling antibodies against NiV in Nepalese 
human and/or bat population. However, Nepal 
harbors well distribution of Pteropus bat. Pig 
farms are widespread throughout the country. 
Nepal also has significant pork eating ethnic 
communities. This clearly outlines the possibility 
of surveilling NiV in bats and/or pigs of Nepal. 
Furthermore, Nepal and India share open 
border without medical surveillance and 
population mobility is higher in the border 
region. This further adds possible risk of viral 
transmission in Nepal. Thus, Nepal is at high 
risk of potential NiV outbreak. 
Conclusion 
Twenty years ago, NiV unveiled itself to the 
world causing significant morbidity and 
mortality. Initially NiV shattered the pig-
farming industry in Malaysia, and is continually 
causing outbreaks in Indian subcontinent. The 
natural reservoir Pteropus bat is widespread, 
thus outbreaks can occur in any risk zones. The 
recent outbreak in India has again increased the 
concern of NiV as potential threat to human 
health. Governments and universities should 
fund research to develop vaccine or drug against 
NiV to neutralize the potential threat. All high 
risk countries including Nepal, should be well 
prepared to tackle the possible future 
catastrophe. 
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